JPWO2020005887A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020005887A5 JPWO2020005887A5 JP2020572525A JP2020572525A JPWO2020005887A5 JP WO2020005887 A5 JPWO2020005887 A5 JP WO2020005887A5 JP 2020572525 A JP2020572525 A JP 2020572525A JP 2020572525 A JP2020572525 A JP 2020572525A JP WO2020005887 A5 JPWO2020005887 A5 JP WO2020005887A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- pharmaceutically acceptable
- unsubstituted
- acceptable salt
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 48
- 150000003839 salts Chemical class 0.000 claims description 46
- 208000019622 heart disease Diseases 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- -1 aminocarbonylamino, aminocarbonyloxy Chemical group 0.000 claims description 6
- 230000000747 cardiac effect Effects 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims description 6
- 210000002235 sarcomere Anatomy 0.000 claims description 6
- 230000002861 ventricular Effects 0.000 claims description 6
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 4
- 206010052337 Diastolic dysfunction Diseases 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 230000000414 obstructive effect Effects 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 208000004990 Cardiorenal syndrome Diseases 0.000 claims description 2
- 208000002330 Congenital Heart Defects Diseases 0.000 claims description 2
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims description 2
- 208000021908 Myocardial disease Diseases 0.000 claims description 2
- 206010061876 Obstruction Diseases 0.000 claims description 2
- 206010039163 Right ventricular failure Diseases 0.000 claims description 2
- 208000033774 Ventricular Remodeling Diseases 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000004442 acylamino group Chemical group 0.000 claims description 2
- 125000004423 acyloxy group Chemical group 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- KWEDUNSJJZVRKR-UHFFFAOYSA-N carbononitridic azide Chemical compound [N-]=[N+]=NC#N KWEDUNSJJZVRKR-UHFFFAOYSA-N 0.000 claims description 2
- 125000005102 carbonylalkoxy group Chemical group 0.000 claims description 2
- 208000028831 congenital heart disease Diseases 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 208000015210 hypertensive heart disease Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 210000004165 myocardium Anatomy 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000004001 thioalkyl group Chemical group 0.000 claims description 2
- 150000003573 thiols Chemical class 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 10
- 238000000034 method Methods 0.000 description 19
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 3
- 208000011518 Danon disease Diseases 0.000 description 2
- 208000024720 Fabry Disease Diseases 0.000 description 2
- 208000001500 Glycogen Storage Disease Type IIb Diseases 0.000 description 2
- 208000035148 Glycogen storage disease due to LAMP-2 deficiency Diseases 0.000 description 2
- 206010047295 Ventricular hypertrophy Diseases 0.000 description 2
- 230000009787 cardiac fibrosis Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 208000007345 glycogen storage disease Diseases 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 208000003017 Aortic Valve Stenosis Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010027727 Mitral valve incompetence Diseases 0.000 description 1
- 206010029748 Noonan syndrome Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 201000004502 glycogen storage disease II Diseases 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690248P | 2018-06-26 | 2018-06-26 | |
| US62/690,248 | 2018-06-26 | ||
| PCT/US2019/038907 WO2020005887A1 (en) | 2018-06-26 | 2019-06-25 | Cardiac sarcomere inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021529185A JP2021529185A (ja) | 2021-10-28 |
| JPWO2020005887A5 true JPWO2020005887A5 (enExample) | 2022-07-04 |
| JP7438148B2 JP7438148B2 (ja) | 2024-02-26 |
Family
ID=67211970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020572525A Active JP7438148B2 (ja) | 2018-06-26 | 2019-06-25 | 心臓サルコメア阻害剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11964967B2 (enExample) |
| EP (1) | EP3814342B1 (enExample) |
| JP (1) | JP7438148B2 (enExample) |
| WO (1) | WO2020005887A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3740481T1 (sl) | 2018-01-19 | 2024-09-30 | Cytokinetics, Inc. | Analogi dihidrobenzofurana in indena kot zaviralci srčne sarkomere |
| EP3814343B1 (en) * | 2018-06-26 | 2023-01-11 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| EP3814342B1 (en) | 2018-06-26 | 2022-07-27 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| AU2019328556B2 (en) | 2018-08-31 | 2025-09-04 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| KR20230079053A (ko) | 2020-08-28 | 2023-06-05 | 미요카디아, 인크. | 미오신 조절제를 이용한 치료 방법 |
| JP2024508526A (ja) | 2021-03-04 | 2024-02-27 | サイトキネティックス， インコーポレイテッド | 心筋サルコメア阻害剤 |
| JP7751124B2 (ja) * | 2022-01-27 | 2025-10-07 | シーエムエス・リサーチ・アンド・ディベロップメント・プライベイト・リミテッド | ７－アザスピロ［４，５］デカン－６，１０－ジオン化合物の結晶形及びその調製方法 |
| IL316204A (en) | 2022-04-26 | 2024-12-01 | Myokardia Inc | Methods for administering myosin inhibitors |
| CN115894361A (zh) * | 2022-12-28 | 2023-04-04 | 上海合全药业股份有限公司 | 一种钯催化合成1-乙酰基-6-氰基-四氢喹啉的方法 |
| WO2025096779A2 (en) | 2023-11-01 | 2025-05-08 | Bristol Myers Squibb Company | Methods of treatment with a myosin inhibitor using protein levels |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995026325A2 (en) | 1994-03-25 | 1995-10-05 | Isotechnika Inc. | Enhancement of the efficacy of drugs by deuteration |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US5919785A (en) | 1996-04-03 | 1999-07-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US20030158186A1 (en) | 2001-12-21 | 2003-08-21 | Fady Malik | Compositions and methods for treating heart failure |
| KR20050100615A (ko) * | 2003-01-14 | 2005-10-19 | 싸이토키네틱스, 인코포레이티드 | 화합물, 조성물 및 방법 |
| EP1606301A4 (en) | 2003-01-21 | 2006-06-14 | Archemix Corp | APTAMERIC THERAPEUTICS FOR MEDICINAL THERAPY FOR EYES |
| WO2004086865A1 (en) | 2003-03-27 | 2004-10-14 | Cytokinetics, Inc. | Compounds, compositions and methods |
| CN1849121A (zh) | 2003-06-20 | 2006-10-18 | 安姆根有限公司 | 作为缓激肽拮抗剂的哌嗪衍生物 |
| NZ552404A (en) | 2004-06-17 | 2010-04-30 | Cytokinetics Inc | Compounds, compositions and methods |
| US20060173183A1 (en) * | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
| CN101175740A (zh) | 2005-04-22 | 2008-05-07 | 惠氏公司 | 二氢苯并呋喃衍生物和其用途 |
| WO2007078815A2 (en) | 2005-12-16 | 2007-07-12 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| RU2318818C1 (ru) | 2006-04-12 | 2008-03-10 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты) |
| SA08290245B1 (ar) | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
| US20090192168A1 (en) | 2008-01-04 | 2009-07-30 | Alex Muci | Compounds, Compositions and Methods |
| WO2010033701A2 (en) | 2008-09-19 | 2010-03-25 | Genzyme Corporation | Inhibitors of sphingosine kinase 1 |
| MX2011012198A (es) | 2009-05-15 | 2011-12-08 | Novartis Ag | Aril-piridinas como inhibidoras de sintasa de aldosterona. |
| US8592426B2 (en) | 2011-01-24 | 2013-11-26 | Hoffmann—La Roche Inc. | Aryl-benzocycloalkyl amide derivatives |
| US8759380B2 (en) * | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| EP2760830B1 (en) | 2011-09-27 | 2016-08-03 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
| NZ628910A (en) | 2012-01-20 | 2016-02-26 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as p2x7 receptor antagonists |
| SMT202000071T1 (it) | 2013-06-21 | 2020-03-13 | Myokardia Inc | Composti di pirimidinadione contro le condizioni cardiache |
| US9199945B2 (en) | 2013-06-21 | 2015-12-01 | MyoKardia, Inc. | Cycloalkyl-substituted pyrimidinedione compounds |
| ES2678021T3 (es) | 2013-12-11 | 2018-08-08 | Biogen Ma Inc. | Compuestos de biarilo útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología |
| US9663516B2 (en) | 2014-12-18 | 2017-05-30 | MyoKardia, Inc. | Bicyclic-pyrimidinedione compounds |
| JP6712275B2 (ja) | 2015-01-22 | 2020-06-17 | マイオカーディア，インク | 拡張型心筋症（ｄｃｍ）の処置のための４−メチルスルホニル置換ピペリジンウレア化合物 |
| MX2018003845A (es) | 2015-10-02 | 2018-06-18 | Syngenta Participations Ag | Derivados de oxadiazol microbicidas. |
| CN108430997B (zh) | 2015-12-17 | 2021-06-04 | 先正达参股股份有限公司 | 杀微生物的噁二唑衍生物 |
| BR112018012378B1 (pt) | 2015-12-18 | 2022-12-20 | Syngenta Participations Ag | Composto da fórmula (i) e seu uso, composição agroquímica e método de controle ou prevenção de infestação de plantas úteis por microrganismos fitopatogênicos |
| WO2017190107A1 (en) | 2016-04-29 | 2017-11-02 | Board Of Regents, The University Of Texas System | Sigma receptor binders |
| US11066396B2 (en) | 2016-06-23 | 2021-07-20 | Merck Sharp & Dohme Corp. | 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors |
| EP3519416B1 (en) | 2016-09-27 | 2021-03-31 | Merck Sharp & Dohme Corp. | Chromane, isochromane and dihydroisobenzofuran derivatives as mglur2-negative allosteric modulators, compositions, and their use |
| WO2018089433A1 (en) | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PHENYL mTORC INHIBITORS AND USES THEREOF |
| JP2020023442A (ja) | 2016-12-19 | 2020-02-13 | 住友化学株式会社 | オキサジアゾール化合物及び植物病害防除方法 |
| US20200000822A1 (en) | 2017-02-23 | 2020-01-02 | Board Of Regents, The University Of Texas System | Methods of treatment for cancer, sterol homeostasis, and neurological diseases |
| CN110325517B (zh) * | 2017-02-28 | 2021-03-02 | 南京明德新药研发有限公司 | 螺环类化合物及其应用 |
| FI3661514T3 (fi) | 2017-08-04 | 2025-12-12 | Myokardia Inc | Mavakamteeni käytettäväksi hypertrofisen kardiomyopatian hoidossa |
| SI3740481T1 (sl) | 2018-01-19 | 2024-09-30 | Cytokinetics, Inc. | Analogi dihidrobenzofurana in indena kot zaviralci srčne sarkomere |
| WO2019226213A2 (en) | 2018-03-08 | 2019-11-28 | Incyte Corporation | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS |
| US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
| EP3814342B1 (en) | 2018-06-26 | 2022-07-27 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| EP3814343B1 (en) * | 2018-06-26 | 2023-01-11 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| EA202190395A1 (ru) | 2018-08-31 | 2021-06-15 | Ксенон Фармасьютикалз Инк. | Замещенные гетероарилом сульфонамидные соединения и их применение в качестве терапевтических средств |
| AU2019328556B2 (en) | 2018-08-31 | 2025-09-04 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| ES2980885T3 (es) | 2019-07-17 | 2024-10-03 | Cytokinetics Inc | Polimorfos de (R)-N-(5-(5-etil-1,2,4-oxadiazol-3-il)-2,3-dihidro-1H-inden-1-il)-1-metil-1H-pirazol-4-carboxamida |
| IL289884B1 (en) | 2019-07-17 | 2025-09-01 | Cytokinetics Inc | Oral formulations of cardiac sarcomere inhibitors |
| ES2982707T3 (es) | 2019-07-17 | 2024-10-17 | Cytokinetics Inc | Polimorfos de (R)-N-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihidro-1H-inden-1-il)-2-metil-2H-tetrazol-5-carboxamida |
| KR20230079053A (ko) | 2020-08-28 | 2023-06-05 | 미요카디아, 인크. | 미오신 조절제를 이용한 치료 방법 |
| JP2024508526A (ja) | 2021-03-04 | 2024-02-27 | サイトキネティックス， インコーポレイテッド | 心筋サルコメア阻害剤 |
| US20230058927A1 (en) | 2021-07-16 | 2023-02-23 | Cytokinetics, Inc. | Methods for treating hypertrophic cardiomyopathy |
| IL316204A (en) | 2022-04-26 | 2024-12-01 | Myokardia Inc | Methods for administering myosin inhibitors |
-
2019
- 2019-06-25 EP EP19737444.0A patent/EP3814342B1/en active Active
- 2019-06-25 US US17/255,336 patent/US11964967B2/en active Active
- 2019-06-25 WO PCT/US2019/038907 patent/WO2020005887A1/en not_active Ceased
- 2019-06-25 JP JP2020572525A patent/JP7438148B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104119310B (zh) | 作为新的在生理学上可用于硝酰基供体的n‑羟基磺酰胺衍生物及包含其的医药组合物 | |
| JP6801045B2 (ja) | ニトロキシル供与体を含む医薬組成物 | |
| JPWO2019144041A5 (enExample) | ||
| KR100968056B1 (ko) | 오르토 및 메타-치환된 비스아릴 화합물, 이의 제조방법,약제로서의 이의 용도 및 이를 함유하는 약제학적 제제 | |
| CN104672115B (zh) | 作为有生理学价值的硝酰氧基供体的n-羟基磺酰胺衍生物 | |
| EP2799427B1 (en) | Therapeutic compounds | |
| EP2650287B9 (en) | Thiazole Derivative and use thereof as VAP-1 Inhibitor | |
| JPWO2020005887A5 (enExample) | ||
| JP5043645B2 (ja) | カルボン酸 | |
| BR112023017461A2 (pt) | Compostos, composição farmacêutica, métodos de tratamento de doença cardíaca, de uma doença ou afecção associada à cardiomiopatia hipertrófica, de uma doença ou afecção que está associada ao espessamento secundário da parede do ventrículo esquerdo, de uma doença ou afecção associada à pequena cavidade ventricular esquerda e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia miocárdica ou fibrose cardíaca, de uma doença ou afecção selecionada a partir de distrofias musculares e doenças de armazenamento de glicogênio, e, método de inibição do sarcômero cardíaco | |
| EP1666469A1 (en) | Plasminogen activator inhibitor-1 inhibitor | |
| US20020049205A1 (en) | Pyrazole antimicrobial agents | |
| JPWO2020047447A5 (enExample) | ||
| JPWO2020005888A5 (enExample) | ||
| EP2113502B1 (fr) | Composés de type hydrazide et leur utilisation dans des compositions pharmaceutiques pour le traitement des maladies cardiovasculaires | |
| JP2019507136A (ja) | カルボキサミドの製造方法 | |
| JPWO2021011807A5 (enExample) | ||
| JPWO2022187501A5 (enExample) | ||
| US12195441B2 (en) | Para acyl substituted diazacyclohexene derivatives | |
| JPWO2022105852A5 (enExample) | ||
| EP3091001B1 (en) | Diphenylmethyl piperazine derivative and pharmaceutical composition using same | |
| JPWO2021011809A5 (enExample) | ||
| RU2022103863A (ru) | Полиморфы (r)-n-(5-(5-изопропил-1,2,4-оксадиазол-3-ил)-2,3-дигидро-1h-инден-1-ил)-2-метил-2h-тетразол-5-карбоксамида | |
| JP2020520904A5 (enExample) | ||
| JP2007513076A5 (enExample) |